WX (Wuxi Pharmatech) is a competitor and just went public in US with a big market cap, backed by Fidelity and a few other US-known VCs. They have all big pharma as clients, and VRTX is the biggest client with Hep C the target. It is based in Shanghai, and is up 50% from IPO.